Physicians' Academy for Cardiovascular Education

Practical experience and model for optimizing RAASi-based therapy in HF

10' education - July 25, 2023 - Aaron Wong, MD - Bridgend, Wales, UK

Video navigation menu

  • RAASi therapy recommended for HF, CKD and T2DM 00:26
  • Barriers leading to suboptimal implementation of RAASi therapy in clinical practice 01:38
  • Overcoming the barrier with potassium binders: real-world data 03:11
  • Practical guidance for prescribing and monitoring of potassium binders in HF therapy 08:11
  • Summary 08:54

During optimization of RAASi therapy, SZC treatment is prescribed to a patient with HFrEF at a dose of 5 mg at alternate days. The serum potassium level of this patient is 5.5 mmol/L during monitoring. What would you consider for this patient?

  • A. Adjust the frequency of dose of SZC to once daily.
  • B. Increase the dose of SZC to 10 mg alternate days.
  • C. Increase the dose of SZC to 10 mg once daily.
  • D. Keep patient on the current dose.
  • E. Consider down-titration of RAASi-based therapy.


Show transcript

Educational information

This lecture by Aaron Wong, MD was part of the EBAC-accredited symposium "Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia" at ESC Heart Failure in Prague, Czech Republic.


Aaron Wong, MD is a consultant cardiologist and general physician working at the Princess of Wales Hospital, Bridgend, South Wales, United Kingdom. He is the local heart failure lead, and also works as a local principal investigator.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from AstraZeneca.

Find here the slides of the presentation Watch the other videos of this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: